Key Takeaways & Executive Findings
- •• The overall incidence of any adverse drug reaction (ADR) after COVID-19 vaccination is 62.3%, with local reactions being most common. • Serious ADRs are extremely rare (0.02%), confirming the favorable safety profile of COVID-19 vaccines. • mRNA vaccines show a higher incidence of ADRs compared to viral vector vaccines, but both are generally well-tolerated. • These findings provide crucial evidence for healthcare providers and policymakers to reinforce vaccine confidence and informed consent.
Abstract
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.
1. Introduction
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in unprecedented global health and socioeconomic burdens. Vaccination has been a cornerstone of the pandemic response, with multiple vaccines developed at record speed and deployed worldwide. As of early 2025, over 13 billion doses have been administered globally, significantly reducing severe illness, hospitalization, and death.
Despite their proven efficacy, COVID-19 vaccines have been associated with a spectrum of adverse drug reactions (ADRs), ranging from common local reactions like injection site pain to rare but serious events such as thrombosis with thrombocytopenia syndrome. These ADRs have generated public concern and vaccine hesitancy, potentially undermining vaccination campaigns. Therefore, a comprehensive synthesis of the safety profile of COVID-19 vaccines is essential to inform clinical practice and public health policy.
This systematic review and meta-analysis aims to quantify the incidence and types of ADRs following COVID-19 vaccination, based on a large body of evidence from randomized controlled trials and observational studies. By pooling data from diverse populations and vaccine platforms, we provide robust estimates that can guide healthcare professionals and reassure the public regarding vaccine safety.
Loading authentic research manuscript (Pages 1–5)...
Zhang Wei, Li Na, Wang Fang, Chen Yu, Liu Yang (2026). Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-024-01234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the overall incidence of adverse reactions after COVID-19 vaccination?
According to our meta-analysis, the overall incidence of any adverse reaction is 62.3%, with local reactions like injection site pain being most common. Serious adverse reactions are extremely rare, occurring in only 0.02% of cases.
Which COVID-19 vaccine type has a higher incidence of adverse reactions?
Our subgroup analysis found that mRNA vaccines (e.g., Pfizer-BioNTech, Moderna) have a higher incidence of adverse reactions compared to viral vector vaccines (e.g., AstraZeneca, Johnson & Johnson). However, both types are generally well-tolerated.
Are serious adverse reactions common after COVID-19 vaccination?
No, serious adverse reactions are extremely rare, with an incidence of 0.02%. This includes conditions like anaphylaxis and thrombosis with thrombocytopenia syndrome, which are very uncommon.
What are the most common local and systemic reactions?
The most common local reactions are injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions include fatigue (34.6%), headache (28.9%), and myalgia (22.3%).
How can these findings help in clinical practice?
These findings provide evidence-based data that healthcare professionals can use to counsel patients about expected side effects, manage them appropriately, and reinforce the overall safety and benefit of COVID-19 vaccination.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
A Novel Approach for Enhancing the Mechanical Properties of NiTi Shape Memory Alloys via Severe Plastic Deformation
NiTi shape memory alloys (SMAs) are widely used in aerospace, biomedical, and automotive applications due to their unique superelasticity and shape memory effect. However, their limited fatigue life and poor machinability restrict broader adoption. This study introduces a novel severe plastic deformation (SPD) technique, specifically high-pressure torsion (HPT), to refine the microstructure and enhance mechanical properties. The effects of HPT processing parameters on the microstructure, phase transformation behavior, and mechanical properties were systematically investigated. Results show that HPT significantly refines the grain size to the nanocrystalline regime, leading to a substantial increase in hardness and tensile strength while maintaining good ductility. The transformation temperatures are also influenced, offering potential for tailoring functional properties. This work provides a promising route for developing high-performance NiTi SMAs for demanding applications.